Entering text into the input field will update the search result below

Merck's Keytruda shows positive effect in mid-stage bladder cancer study

Oct. 20, 2018 6:38 PM ETMerck & Co., Inc. (MRK) StockBy: Douglas W. House, SA News Editor7 Comments
  • Preliminary data from a Phase 2 clinical trial, KEYNOTE-057, evaluating Merck's (NYSE:MRK) KEYTRUDA (pembrolizumab) in treatment-experienced patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) (cancer confined to the mucosa) or CIS plus papillary disease (long, thin tumors) showed a treatment effect. The results were presented at ESMO in Munich.
  • At month 3, the complete response rate was 38.8% (n=40/103) in patients who failed to respond to standard-of-care Bacillus Calmette-Guérin (BCG) therapy and who were ineligible for or refused radical cystectomy (bladder removal).
  • No new safety signals were observed.
  • NMIBC comprises 80% of bladder cancer cases. 40% of high-risk patients progress to muscle-invasive disease.
  • Development is ongoing.
  • #ESMO

Recommended For You

About MRK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MRK--
Merck & Co., Inc.